Prexton Therapeutics
Plan-les-ouates
About Prexton Therapeutics
Prexton Therapeutics is a Swiss-based biopharmaceutical company, founded in 2012 by Francois Conquet and MS Ventures as part of the Merck Serono Entrepreneur Partnership Program, a facility to support the creation of spin-offs from Merck Serono. Prexton Therapeutics applies a new scientific approach that fully integrates molecular, behavioural and chemistry technologies to address Parkinson’s disease and other brain disorders. Prexton Therapeutics uses its powerful discovery platform to target specific novel compounds focused on the treatment of Parkinson’s disease.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $41.1M
- Funding stage: M&A
- Last round: Series B (Feb 2017)
- Website: prextontherapeutics.com
- Phone: +41227069010
Industries & Categories
Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/prexton-therapeutics-185103 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.